RenovoRx FY2026 EPS Increased by Ascendiant Capital Markets

RenovoRx, Inc. (NASDAQ:RNXT) – Equities research analysts at Ascendiant Capital Markets raised their FY2026 earnings per share (EPS) estimates for RenovoRx in a report issued on Thursday, August 27th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($0.27) per share for the year, up from their previous forecast of ($0.29). Ascendiant Capital Markets has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.25) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($0.20) EPS.

RenovoRx (NASDAQ:RNXT) last posted its earnings results on Wednesday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. RenovoRx had a negative net margin of 621.71% and a negative return on equity of 135.11%. The business had revenue of $0.91 million for the quarter, compared to analyst estimates of $0.70 million.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of RenovoRx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Wall Street Zen upgraded RenovoRx from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

RenovoRx Trading Up 9.3%

Shares of RNXT stock opened at $2.11 on Wednesday. The company has a market capitalization of $95.22 million, a PE ratio of -6.81 and a beta of 1.12. The firm has a fifty day simple moving average of $1.10 and a 200-day simple moving average of $0.98. RenovoRx has a twelve month low of $0.70 and a twelve month high of $2.20.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC raised its stake in shares of RenovoRx by 30.8% in the 1st quarter. AIGH Capital Management LLC now owns 3,706,197 shares of the company’s stock valued at $3,682,000 after purchasing an additional 872,303 shares in the last quarter. Bleichroeder LP increased its holdings in RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after buying an additional 61,379 shares during the last quarter. Geode Capital Management LLC raised its stake in RenovoRx by 9.9% during the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after buying an additional 31,730 shares in the last quarter. Wealthspire Advisors LLC bought a new position in RenovoRx during the 4th quarter worth approximately $212,000. Finally, Citadel Advisors LLC acquired a new position in RenovoRx in the third quarter worth $154,000. 3.10% of the stock is owned by institutional investors and hedge funds.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.